^
Association details:
| Biomarker: | VHL mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Differential sensitivity of renal carcinoma cells to doxorubicin and epigenetic therapeutics depends on the genetic background
Published date:
02/16/2021
Excerpt:
Two renal cell carcinoma (RCC) cell lines, Caki-1 and 786-0, with different genetic makeup of p53 and VHL were treated with doxorubicin...Important findings of this study suggest that doxorubicin is more cytotoxic to primary renal cancer 786-0 cells with mutant VHL and p53 than the metastatic Caki-1 cells with wild-type VHL and p53...
DOI:
10.1007/s11010-021-04076-7
